CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.
Ang JE, Olmos D, de Bono JS.
Br J Cancer. 2009 Mar 10;100(5):671-5. Epub 2009 Feb 17.
PMID: 19223900
doi:10.1038/sj.bjc.6604904
Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.
Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS.
J Clin Oncol. 2008 Oct 1;26(28):4563-71. Epub 2008 Jul 21.
PMID: 18645193
DOI: 10.1200/JCO.2007.15.9749
"SCIENTISTS have shown that a new class of cancer drugs called PARP inhibitors, currently being tested in clinical trials to treat breast and ovarian cancer could have dramatic results when used to treat other solid tumours, according to work presented at the NCRI Cancer Conference today. "
Berberine and Coptidis rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations.
Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y.
J Ethnopharmacol. 2009 Oct 29;126(1):5-17. Epub 2009 Aug 15.
PMID: 19686830
doi:10.1016/j.jep.2009.08.009
Conclusions
The modern evidences of treating cancer with Huanglian and berberine have a strong linkage with traditional concept and rules of using Huanglian in CM practice. As anticancer candidates with low toxicity, berberine and its altered structure, as well as Huanglian and its formulae, will attract scientists to pursue the potential anticancer effects and the mechanisms by using technologies of genomics, proteomics and other advanced approaches. On the other hand, relatively few in vivo studies have been conducted on anticancer effects of Huanglian and berberine. The clinical application of berberine or Huanglian as novel cancer therapeutic agents requires in vivo validations and further investigations of their anticancer mechanisms.
In the largest study of its kind to date, Stanford University School of Medicine researchers have shown that women related to a patient with a breast cancer caused by a…
Creative BioLabs is an US based biotech service provider.It has extensive experience in fully human monoclonal antibody. Call 1-631-871-5806 or email at contact@creative-biolabs.com for details. Learn more by visiting http://www.creative-biolabs.com/full-human-antibody-from-humanized-mouse-derived-antibody-library.html.
Creative Biolabs are pleased to introduce our full human antibody from humanized mouse-derived antibody library service, we have successfully produced several functional libraries.
Creative BioLabs is an US based biotech service provider.It has extensive experience in internalizing antibody and peptides. Call 1-631-871-5806 or email at contact@creative-biolabs.com for details.